Diffusion, Adoption, and Implementation of Pharmacotherapies in Alcohol Tx

酒精治疗中药物疗法的传播、采用和实施

• 批准号: 7447326
• 负责人: Amanda J Abraham
• 金额: $ 4.75万
• 依托单位: UNIVERSITY OF GEORGIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7447326
• 关键词: Address; Administrator; Adopted; Adoption; Alcohol dependence; Alcoholism; Alcohols; Attitude; Belief; Characteristics; Classification; Clinical; Communities; Data; Data Analyses; Data Collection; Development; Diffusion; Effectiveness; Evidence based practice; Funding; Funding Agency; Future; Goals; Health; Health Personnel; Health Services; Improve Access; Injectable; Interview; Knowledge; Learning; Literature; Longitudinal Studies; Mails; Measures; Medical Technology; Modeling; Monitor; Movement; Naltrexone; Pattern; Persons; Pharmaceutical Preparations; Pharmacological Treatment; Pharmacotherapy; Philosophy; Private Sector; Process; Professional counselor; Questionnaires; Research; Research Personnel; Sampling; Shapes; Site; Specific qualifier value; Structure; Substance abuse problem; Suspension substance; Suspensions; System; Techniques; Technology; Technology Transfer; Telephone; Testing; Time; Training and Education; United States Food and Drug Administration; United States National Institutes of Health; United States Substance Abuse and Mental Health Services Administration; acamprosate; addiction; alcohol abuse therapy; base; follow-up; innovation; programs; research to practice; theories; treatment center; treatment program; trend

DESCRIPTION (provided by applicant): Despite recent advances in the development of pharmacotherapies for the treatment of alcohol dependence, the treatment community has been slow to adopt and implement these evidence-based practices. The proposed research addresses this research-to-practice gap by examining the adoption, diffusion, and implementation of the three most recent FDA approved pharmacotherapies for the treatment of alcohol dependence-naltrexone, acamprosate, and Vivitrol. The specific aims of the proposed research are threefold: (1) Describe, compare, and contrast trends in the adoption, diffusion and implementation of naltrexone, acamprosate.and Vivitrol by addiction treatment programs. (2) Identify key structural and workforce characteristics that facilitate or impede diffusion, adoption and implementation of these three pharmacotherapies over time. (3) Specify, test, and compare the "fit" of multivariate models predicting the adoption and implementation of the three pharmacotherapies. Data for the proposed research will be taken from the National Treatment Center Study (NTCS), a nationally representative, longitudinal study of 403 privatesector addiction treatment programs. Present and future NTCS data collections provide researchers the opportunity to examine the "real time" diffusion of acamprosate and Vivitrol into everyday treatment practice and to compare overall diffusion trends with naltrexone which received FDA approval in 1994. The proposed research will make significant contributions to the field of substance abuse health services by testing models of adoption and implementation as a product of both organizational and workforce level characteristics, testing for interactions between key organizational and workforce predictors, and utilizing multi-level and longitudinal data analysis techniques. The results of this research will provide important information about the organizational and workforce characteristics that shape the movement of research based medical technologies into everyday practice and provide a greater understanding of the barriers to adoption and implementation of pharmacotherapies. This information will be relevant to treatment providers, health researchers, and health policymakers as they seek to bridge the "research to practice gap" and improve access to quality treatment for persons suffering from alcoholism.

描述（由申请人提供）：尽管在用于治疗酒精依赖的药物治疗的开发方面取得了进步，但治疗界采用和实施这些基于证据的实践的速度却很慢。拟议的研究通过研究了三种最新的FDA批准的药物治疗，以治疗酒精依赖性 - 纳特脱甲酮，丙型苯甲酸盐和乙醇，从而解决了这一研究对实践差距。拟议研究的具体目的是三重：（1）描述，比较和对比趋势，在成瘾治疗计划中采用，扩散和实施Naltrexone，Acamprosate.和Vivitrol。 （2）确定促进或阻碍扩散，采用和实施这三种药物治疗的关键结构和劳动力特征。 （3）指定，测试和比较多元模型的“拟合”，以预测三种药物治疗的采用和实施。拟议研究的数据将取自国家治疗中心研究（NTCS），这是一项全国代表性的，对403个私人私人成瘾治疗计划的纵向研究。当前和未来的NTCS数据收集为研究人员提供了机会，可以检查分支含量和体内的“实时”扩散到日常治疗实践中，并将整体扩散趋势与Naltrexone进行比较，而Naltrexone在1994年获得了FDA的批准。拟议的研究将对对滥用现场的效果进行促进，以实现的范围，以实现的范围，以实现范围，以实现的范围，以实现的范围，该产品的生产成果，这些产品的范围均可通过有效的产品来实施，该产品的产品既可以采用了产品，又可以实现产品的产品。组织和劳动力预测指标，并利用多层次和纵向数据分析技术。这项研究的结果将提供有关组织和劳动力特征的重要信息，这些信息可以塑造基于研究的医疗技术向日常实践的运动，并对采用和实施药物治疗的障碍有更深入的了解。这些信息将与治疗提供者，卫生研究人员和卫生决策者有关，因为他们试图弥合“研究差距”，并改善患有酒精中毒的人获得优质治疗的机会。